Exploring novel approaches to vaginal drug delivery

Recent Patents on Drug Delivery and Formulation

Volumn 5, Issue 2, 2011, Pages 82-94

  Gupta, Sonal ^a   Gabrani, Reema ^a   Ali, Javed ^b   Dang, Shweta ^a  

^a JAYPEE INSTITUTE OF INFORMATION TECHNOLOGY   (India)

^b HAMDARD UNIVERSITY   (India)

Author keywords

Drug delivery; Hydrogels; Liposomes; Mucoadhesive polymers; Nanoemulsions; Nanoparticles; Vaginal route

Indexed keywords

5 BROMO 6 METHOXY 5,6 DIHYDRO 3' AZIDOTHYMIDINE 5' (4 BROMOPHENYL)METHOXYALANINYL PHOSPHATE; ACICLOVIR; ALGINIC ACID; ANTIRETROVIRUS AGENT; CALCITONIN; CANDID V; CARRAGEENAN; CELLULOSE; CHITOSAN; CLOTRIMAZOLE; DENDRIMER; DRUG CARRIER; ECONAZOLE; GELATIN; HYALURONIC ACID; KETOCONAZOLE; LIPOSOME; METRONIDAZOLE; MICROBICIDE; NANOCARRIER; NANOPARTICLE; NONOXINOL 9; POLYACRYLIC ACID; POLYMER; POVIDONE; PROGESTERONE; S NITROSOGLUTATHIONE; SILVER NANOPARTICLE; THIOMER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANADOCENE DITHIOCARBAMATE; WHI 07;

ABSENCE OF SIDE EFFECTS; ARTICLE; CYTOTOXICITY TEST; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG IMPLANT; DRUG PENETRATION; DRUG SAFETY; DRUG SOLUBILITY; FEMALE INFERTILITY; FUNCTIONAL ANATOMY; GENITAL HERPES; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROGEL; MEMBRANE PERMEABILITY; MICELLE; MUCOADHESION; NANOEMULSION; NANOENCAPSULATION; NONHUMAN; PH MEASUREMENT; PHYSICAL CHEMISTRY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; TABLET FORMULATION; TEMPERATURE SENSITIVITY; TRANSVAGINAL MESH PATCH; URINARY TRACT INFECTION; VAGINA CANDIDIASIS; VAGINA DISCHARGE; VAGINA MUCOSA; VAGINA MYCOSIS; VAGINAL BURNING SENSATION; VAGINAL PRURITUS; VAGINITIS;

ABSORPTION; ADMINISTRATION, INTRAVAGINAL; CARRAGEENAN; CELLULOSE; CHITOSAN; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; HYDROGELS; LIPOSOMES; MICELLES; PATENTS AS TOPIC; VAGINA;

EID: 79955643671     PISSN: 18722113     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221111795471418     Document Type: Article

References (120)

1. Woolfson AD. In: Roberts MS, Rathbone MJ, Hadgraft J, LaneME, Eds. Intravaginal Drug Delivery Technologies. New York:Marcel Dekker 2008: 754-74.
2. Macht DI. The absorption of drugs and poisons through the vagina. J Pharmacol Exp Ther 1918; 10: 509-22.
3. Nayak BS, Ellaiah P, Sudhahar D. Novel approaches in vaginaldrug delivery systems for local and systemic treatments. J PharmRes 2010; 3(4): 675-80.
4. Desai A, Lee M. Gibaldi's Drug Delivery System inPharmaceutical Care. American Society of Health- SystemPharmacists: Bethesda 2007.
5. Merabet J, Thompson D, Levinson RS. Advancing vaginal drugdelivery. Expert Opin Drug Deliv 2005; 2(4): 769-77.
6. Richardson JL, Illum L. Routes of delivery: Case studies. AdvDrug Del Rev 1992; 8: 341-66.
7. De Ziegler D, Bulletti C, De Monstier, Jaaskelainen AS. The firstuterine pass effect. Ann NY Acad Sci 1997; 828: 291-9.
8. Hussain A, Ahsan F. The vagina as a route for systemic drugdelivery. J Control Release 2005; 103(2): 301-13.
9. Chatterjee A, Bhowmik BB, Kumar L. An overview of intravaginaldrug delivery. J Pharm Res 2009; 2(4): 698-700.
10. Greco, J.C., McGinity, J.W. Vaginal progesterone tablet. US5084277 (1992).
11. Niederer, R.R., Zulliger, H.W. Medicated suppository. US4698359(1987).
12. Milankovits, M. Pharmaceutical compositions, mainly vaginalsuppository, containing many different active ingredients.US6432935 (2002).
13. Ahmad, N., Brummer, B., Dalal, N.M., Toddywala, R. Antifungalvaginal cream composition. US5514698 (1996).
14. Bentley, C.L., Feldtmose, K. Vaginal pharmaceutical compositionsand methods for preparing them. US7456207 (2008).
15. Yang, S.P., Huang, L., Martin, S.M., Villanueva, J., Greene, S., Arehart, K., Sayre, C., Johnson, R.B. Xylitol for treatment ofvaginal infections. US7619008 (2009).
16. Dahl, T.C. Pharmaceutical vaginal gel comprising tenofovir. EP1773296 (2009).
17. Horrobin, D.F. Method of treating vulvar dystrophy and vaginaldryness. US5380757 (1995).
18. Burnhill, M.S. Vaginal Sponge. US3762414 (1973).
19. Myhling, J. Vaginal sponge delivery system. US5527534 (1996).
20. Egidio, M., Gabriele, R.L., Desai, S., Massimo, G. Pharmaceuticalcompositions containing rifaximin for treatment of vaginalinfections. US5314904 (1994).
21. Tripp, H.A., Rackley, R. Pelvic floor reconstruction. US6197036(2001).
22. Sneider, V.R. Tampon and drug delivery device. US4318405(1982).
23. Kubicki, J., Rink, R. Tampon for medical or hygienic purposes andmethod of making the same. US5201326 (1993).
24. Pauletti, G.M., Wilson, M., Soderstrom, R., Kishorkumar, D.J.,Ritschel, W.A. Coated vaginal device for delivery of anti-migraineand anti-nausea drugs. US7744916 (2010).
25. Roseman, R.J. Pharmaceutical devices and method. US3920805(1975).
26. Schopflin, G., Laudahn, G., Muhe, B., Hartmann, H., Windt, F. Vaginal ring. US4155991 (1979).
27. Krause U. Results of single-dose treatment of vaginal mycoses with500 mg Canesten vaginal tablets. Chemotherapy 1982; 28(1): 99-105.
28. Eriksen PS, Rasmussen H. Vagifem. A new low-dosage estradiolpreparation for local treatment of postmenopausal urogenitalatrophy. Ugeskr Laeger 1992; 154(16): 1122-4.
29. Ozkinay E, Terek MC, Yayci M, Kaiser R, Grob P, Tuncay G. Theeffectiveness of live lactobacilli in combination with low doseestriol (Gynoflor) to restore the vaginal flora after treatment ofvaginal infections. BJOG 2005; 112(2): 234-40.
30. Embil Pharmaceuticals. Product Information. Gynomax Pessary.Available at:http://www.embil.com/default.asp?PAG00_CODE=PRDTR01&MMG00_CODE=002&MMH00_CODE=03EN (Accessed on: Nov11, 2010).
31. Drugs Information Online. Terazole 3. Available at: http://www.drugs.com/mtm/terazol-3.html (Accessed on: Sep 29,2010).
32. Faro S, Skokos CK. The efficacy and safety of a single dose ofClindesse vaginal cream versus a seven-dose regimen of Cleocinvaginal cream in patients with bacterial vaginosis. Infect Dis ObstetGynecol 2005; 13(3): 155-60.
33. Brown D, Henzl MR, Kaufman RH. Butoconazole nitrate 2% forvulvovaginal candidiasis. New, single-dose vaginal creamformulation vs. seven-day treatment with miconazole nitrate.Gynazole 1 Study Group. J Reprod Med 1999; 44(11): 933-8.
34. Drugs Information Online. Synthetic Conjugated Estrogens-A.Available at: http://www.drugs.com/cdi/synthetic-conjugatedestrogens-a-cream.html (Accessed on: Sep 18, 2010).
35. Propst AM, Hill JA, Ginsburg ES, Hurwitz S, Politch J, Yanushpolsky EH. A randomized study comparing Crinone 8%and intramuscular progesterone supplementation in in vitrofertilization-embryo transfer cycles. Fertil Steril 2001; 76(6): 1144-9.
36. Mayer KH, Peipert J, Fleming T, Fullem A, Moench T, Cu-Uvin S, et al. Safety and tolerability of BufferGel, a novel vaginalmicrobicide, in women in the United States. Clin Infect Dis 2001;32: 476-82.
37. Jones RN, Bale MJ, Hoban D, Erwin ME. In vitro antimicrobialactivity of tioconazole and its concentration in vaginal fluidsfollowing topical (vagistat-1 6.5%) application. Diagn Microbiol Infect Dis 1993; 17(1): 45-51.
38. Drugs Information Online. Gynecure. Available at: http://www.drugs.com/cons/gyne-cure-topical.html (Accessed on:Nov 12, 2010).
39. Rubio B. Clinical evaluation of the effectiveness of miconazole invaginal candidiasis. Gynecol Obstet Mex 1974; 35(209): 233-9.
40. Drugs Information Online. Miconazole nitrare. Femizol-M.Available at: http://www.drugs.com/monograph/miconazolenitrate.html (Accessed on: Nov 13, 2010).
41. Khanna N, Dalby R, Tan M, Arnold S, Stern J, Frazer N. Phase I/IIclinical safety studies of terameprocol vaginal ointment. Gynecol Oncol 2007; 107(3): 554-62.
42. Serfaty D. The contraceptive sponge. Entret Bichat Petie Salpetriere Ther 1982; 1: 225-8.
43. Creatsas G, Elsheikh A, Colin P. Safety and tolerability of the newcontraceptive sponge Protectaid. Eur J Contacept Reprod HealthCare 2002; 7(2): 91-5.
44. Foamix. Foamix Unveils Innovative Vaginal Foam. Available at: http://www.foamix.co.il/InnovativeVaginal.html (Accessed on:Nov 17, 2010).
45. Candida Free. Resources. Available at: www.candidafree.net/resource_17.htm (Accessed on: Nov 25,2010).
46. Eriksen B. A randomized, open, parallel-group study on thepreventive effect of an estradiol-releasing vaginal ring (Estring) onrecurrent urinary tract infectionsin postmenopausal women. Am JObstet Gynecol 1999; 180(5): 1072-9.
47. Drug Information Online. Femring Ring. Available at: http://www.drugs.com/cdi/femring-ring.html (Accessed on: Sep 26, 2010).
48. America Rx.com. Summer's Eve Douche. Available at: http://www.americarx.com/brandpages/summers_eve_douche_productname_asc_25_1.html (Accessed on: Dec 4, 2010).
49. Drug Information Online. Massengil feminine cleansing wash. Available at: http://www.drugs.com/drp/massengill-femininecleansing-wash.html (Accessed on: Aug 19, 2010).
50. Drug Information Online. Betadine Douche. Availble at: http://www.drugs.com/cdi/betadine-douche.html (Accessed on:Aug 29, 2010).
51. Wilson KJW. Anatomy and Physiology in Health and Illness. 8thed. Churchill Livingstone, Longman, Asia Ltd: Hong Kong 1996.
52. Jain NK. Controlled and novel drug delivery. 1st ed. CBSPublishers and Distributors, New Delhi 1997.
53. Vasir JK, Tambwekar K, Garg S. Bioadhesive microspheres as acontrolled drug delivery system. Int J Pharm 2003; 255(1-2): 13-32.
54. Edsman K, Hagerstrom H. Pharmaceutical applications ofmucoadhesion for the non-oral routes. J Pharm Pharmacol 2005;57(1):3-22.
55. Roy S, Pal K, Anis A, Pramanik K, Prabhakar B. Polymers inMucoadhesive Drug Delivery System: A brief note. Des Monomers Polym 2009; 12(6): 483-95.
56. El-Kamel A, Sokar M, Naggar V, Al Gamal S. Chitosan andSodium alginate-based bioadhesive vaginal tablets. AAPS Pharm Sci 2002; 4(4): E44.
57. Ceschel GC, Maffei P, Borgia SL, Ronchi S, Rossi S. Developmentof a mucoadhesive dosage form for vaginal administration. Drug Dev Ind Pharm 2001; 27(6): 541-7.
58. Robinson, J.R. Bioadhesive compositions and methods of treatmenttherewith. US4615697 (1986).
59. Baichwal, A.R. Bioadhesive tablet for non-systemic use products. US5330761 (1994).
60. Santus, G., Bottoni, G., Sala, G. Pharmaceutical controlled-releasecomposition with bioadhesive properties. US5472704 (1995).
61. Durrani, M.J. Prolonged release bioadhesive vaginal gel dosageform. US6159491 (2000).
62. Garg S, Vermani K. The scope and potential of vaginal drugdelivery. Pharm Sci Technol To 2000; 3(10): 359-64.
63. Smart JD, Kellaway IW, Worthington HE. An in vitro investigationof mucosa-adhesive materials for use in controlled drug delivery. J Pharm Pharmacol 1984; 36(5): 295-9.
64. Acarturk F. Mucoadhesive vaginal drug delivery systems. Recent Pat Drug Deliv Formul 2009; 3(3): 193-205.
65. Karasulu HY, Hilmio S, Metin DY, Guneri T. Efficacy of a newketoconazole bioadhesive vaginal tablet on Candida albicans.Farmaco 2004; 59(2): 163-7.
66. Bonferoni MC, Sandri G, Rossi S, Ferrari F, Gibin S, Caramella C. Chitosan citrate as multifunctional polymer for vaginal deliveryevaluationof penetration enhancement and peptidase inhibitionproperties. Eur J Pharm Sci 2008; 33(2): 166-76.
67. Gavini E, Sanna V, Juliano C, Bonferoni MC, Giunchedi P. Mucoadhesive vaginal tablets as veterinary delivery system for thecontrolled release of an antimicrobial drug, acriflavine. AAPS PharmSci 2002; 3(3): E20.
68. Zhao, X., Burd, K.A. Vaginal lubricant comprising hyaluronic acid. WO2009066102 (2009).
69. Asane GS, Nirmal SA, Rasal KB, Naik AA, Mahadik MS, Rao YM. Polymers for mucoadhesive drug delivery system: A currentstatus. Drug Dev Ind Pharm 2008; 34(11): 1246-66.
70. Maguire RA, Zacharopoulos VR, Phillips DM. Carrageenan- basednonoxynol-9 spermicides for prevention of sexually transmittedinfections. Sex Transm Dis 1998; 25(9): 494- 500.
71. Liu Y, Zhu Y, Wei G, Lu W. Effect of carrageenan on poloxamerbasedin situ gel for vaginal use: Improved in vitro and in vivosustained-release properties. Eur J Pharm Sci 2009; 37(3-4): 306-12.
72. El-Kamel A, Sokar M, Naggar V, Gamal SA. Chitosan and sodiumalginate-based bioadhesive vaginal tablets. AAPS PharmSci 2002;4 (4): E44.
73. Lee CH, Dharmala K, Yoo JW. The physicodynamic properties ofmucoadhesive polymeric films developed as female controlled drugdelivery system. Int J Pharm 2006; 309(1-2): 139-45.
74. Samuel AJ, Kulkarni M, Tambe R. Thiomers: Forms, features andformulations. J Chem Pharm Res 2010; 2(6): 316-23.
75. Cevher E, Sensoy D, Taha M, Araman A. Effect of thiolatedpolymers to textural and mucoadhesive properties of vaginal gelformulations prepared with polycarbophil and chitosan. AAPS Pharm Sci Tech 2008; 9(3): 953-65.
76. Baloglu E, Senyigit ZA, Karavana SY, Schnurch AB. Strategies toprolong the intravaginal residence time of drug delivery systems. JPharm Pharmaceut Sci 2009; 12(3): 312-36.
77. Buckheit Jr RW, Watson KM, Morrow KM, Ham AS. Development of topical microbicides to prevent the sexualtransmission of HIV. Antivir Res 2010; 85(1): 142-58.
78. Dobaria N, Badhan A, Mashru R. A novel itraconazole bioadhesivefilm for vaginal delivery: Design, optimization, andphysicodynamic characterization. AAPS Pharm SciTech 2009;10(3): 951-9.
79. Yoo JW, Acharya G, Lee CH. In vivo evaluation of vaginal filmsfor mucosal delivery of nitric oxide. Biomaterials 2009; 30(23-24):3978-85.
80. Repka, M.A., Repka, S.L., McGinity, J.W. Bioadhesive hot-meltextruded film for topical and mucosal adhesion applications anddrug delivery and process for preparation thereof. US6375963 (2002).
81. Albertini B, Passerini N, Sabatino MD, Vitali B, Brigidi P, Rodriguez L. Polymer-lipid based mucoadhesive microspheresprepared by spray-congealing for the vaginal delivery of econazolenitrate. Eur J Pharm Sci 2009; 36(4-5): 591-601.
82. Yokoyama M. Drug targeting with nano-sized carrier. J ArtifOrgans 2005; 8(2): 77-84.
83. Webber, S.E., Martin, T.J. pH Dependent polymer micelles. US5955509 (1999).
84. Modi, P. Mixed micellar drug delivery system and method ofpreparation. US6350458 (2002).
85. Ruvalcaba AM, Sanchez-Diaz JC, Becerra F, Cruz-Barba LE, Gonzalez-Alvarez A. Swelling characterization and drug deliverykinetics of polyacrylamide-co-itaconic acid/chitosan hydrogels. Exp Polymer Lett 2009; 3(1): 25-32.
86. Sawhney, A.S. Composite hydrogel drug delivery systems.US6632457 (2003).
87. Haslam, J.L., Higuchi, T., Mlodozeniec, A.R. Drug delivery systemutilizing thermosetting gels. US4478822 (1984).
88. Lara HH, Ixtepan-Turrent L, Garza-Trevino EN, Rodriguez-Padilla C. PVP-coated silver nanoparticles block the transmissionof cell-free and cell-associated HIV-1 in human cervical culture. J Nanobiotechnology 2010; 8:15.
89. Chang, N.J. Stable suspension formulations of bioerodible polymermatrix microparticles incorporating drug loaded ion exchange resinparticles. US5275820 (1994).
90. Ragavan, V.V., DiPiano, G.M. Pharmaceutical preparations andmethods for their administration. US5993856 (1999).
91. Ranade W. Site specific drug delivery using liposomes as carriers. J Clin Pharmacol 1989; 29(8): 685-94.
92. Pavelic Z, Skalko-Basnet N, Schubert R. Liposomal gels forvaginal drug delivery. Int J Pharm 2001; 219(1-2): 139-49.
93. D'Cruz OJ, Samuel P, Uckun FM. Conceival, a novelnoncontraceptive vaginal vehicle for lipophilicmicrobicides. AAPS Pharm SciTech 2005; 06(01): E56-64.
94. Pavelic Z, Skalko-Basnet N, Filipovic-Grcic J, Martinac A, Jalsenjak I. Development and in vitro evaluation of a liposomalvaginal delivery system for acyclovir. J Control Release 2005;106(1-2): 34-43.
95. Zeng F, Zimmerman SC. Dendrimers in supramolecular chemistry:From molecular recognition to self-assembly. Chem Rev 1977;97(5): 1681-712.
96. Pushkar S, Philip A, Pathak K, Pathak D. Dendrimers:Nanotechnology Derived Novel Polymers in Drug Delivery. Indian J Pharm Edu Res 2006; 40(3): 153-8.
97. Jiang YH, Emau P, Cairns JS, Flanary L, Morton WR, McCarthy TD, et al. SPL7013 gel as a topical microbicide for prevention ofvaginal transmission of SHIV89.6P in macaques. AIDS Res Hum Retroviruses 2005; 21(3): 207-13.
98. NanoBio Corporation. Platform Tech. Available at: http://www.nanobio.com/Platform-Technology/NanoStat-Platform.html (Accessed on: Oct 26, 2010).
99. Anselem, S., Lowell, G.H., Aviv, H., Friedman, D. Solid fatnanoemulsions as vaccine delivery vehicles. US5716637 (1998).
100. Poli, S., Mailland, F., Moro, L. Microemulsion pharmaceuticalcompositions for the delivery of pharmaceutically active agents. US5759566 (1998).
101. Gizurarson, S., Heron, I. Pharmaceutical preparation for topicaladministration of antigens and/or vaccines to mammals via amucosal membrane. US5942237 (1999).
102. D'Cruz OJ, Uckun FM. Influence of long-term stability conditionson microbicidal nucleoside prodrug (WHI-07)-loaded gelmicroemulsion. AAPS Pharm SciTech 2006; 7(3): 73.
103. D'Cruz OJ, Uckun FM. Dawn of non-nucleoside inhibitor-basedanti-HIV microbicides. J Antimicrob Chemother 2006; 57(3): 411-23.
104. Bachhav YG, Patravale VB. Microemulsion-based vaginal gel ofclotrimazole: formulation, in vitro evaluation, and stability studies. AAPS Pharm Sci Tech 2009; 10(2): 476-81.
105. D'Cruz OJ, Uckun FM. Preclinical evaluation of a dual-actingmicrobicidal prodrug WHI-07 in combination with vanadocenedithiocarbamate in the female reproductive tract of rabbit, pig, andcat. Toxicol Pathol 2007; 35(7): 910-27.
106. Jacquetin B, Fatton B, Rosenthal C, Clave H, Debodinance P, Hinoul P, et al. Total transvaginal mesh (TVM) technique fortreatment of pelvic organ prolapse: A 3-year prospective follow-upstudy. Int Urogyenecol J Pelvic Floor Dysfunct 2010; 21(12):1455-62.
107. Ulmsten, U., Schwartz, B., Leibowitz, R. Mesh for pelvic floorrepair. US7087065. (2006).
108. Larson KA, Hsu Y, De Lancey JO. The relationship betweensuperior attachment points for anterior wall mesh operations andthe upper vagina using a 3-dimensional magnetic resonance modelin women with normal support. Am J Ostet Gynecol 2009; 200(5):554, e1-6.
109. Verma RK, Garg S. Current status of drug delivery technologiesand future directions. Pharmaceutical Technology On-Line 2001;25(2): 1-14.
110. Barnhart K. Vaginal drug delivery. IDrugs 1999; 2: 756-9.
111. Rupp R, Rosenthal SL, Stanberry LR. Vivagel (SPL7013 Gel): Acandidate dendrimer-microbicidefor the prevention of of HIV andHSV infection. Int J Nanomedicine 2007; 2(4): 56-6.
112. Drugs Information Online. Clotrimazole Consumer Information.Available at: www.drugs.com/mtm/mycelex-g.html (Accessed on:Nov 26, 2010).
113. ASIA Pharmaceutical Industries. Product Search. Available at: http://www.asiapharma-syria.com/en/product-search/Hormones(Accessed on: Dec 8, 2010).
114. das Neves J, da Silva MV, Goncalves MP, Amaral MH, Bahia MF. Rheological properties of vaginal hydrophilic polymer gels. CurrDrug Deliv 2009; 6(1): 83-92.
115. Wain AM. Metronidazole vaginal gel 0.75% (Metrogel-vaginal): abrief review. Infect Dis Obstet Gynecol 1998; 6(1): 3-7.
116. Martin PL. Safety and efficacy of Estrace (micronized 17 betaestradiol). Int J Fertil 1986; 31: 39-44.
117. Lucioni A, Rapp DE, Gong EM, Reynolds WS, Fedunok PA, Bales GT. The surgical technique and early postoperative the GynecareProlift pelvic floor repair system. Can J Urol 2008; 15(2): 4004-8.
118. RxList. The Internet Drug Index. Aci-Jel. Available at: http://www.rxlist.com/aci-jel-drug.htm (Accessed on: Dec 20,2010).
119. Netdoctor. Medicines. Zidoval. Available at: www.netdoctor.co.uk/medicines/100002840.html (Accessed on: Dec 18, 2010).
120. Sayani AP, Chien YW. Systemic delivery of peptides and proteinsacross absorptive mucosae. Crit Rev Ther Drug Carrier Syst 1996;13(1-2): 85-184.